BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has commenced an underwritten public offering of its shares of common stock and accompanying common warrants and, in lieu of its shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock and accompanying common warrants.

波士顿，2024年6月27日（环球通讯社）--Elicio Therapeutics，Inc.（纳斯达克：ELTX，“Elicio Therapeutics”或“Elicio”），一家临床阶段的生物技术公司，开发了一系列用于治疗癌症的新型免疫疗法，今天宣布，它已经开始承销其普通股和伴随的普通认股权证的股票，并代替其普通股股票，向某些选择的投资者提供预先出资的认股权证，以购买普通股和伴随的普通认股权证的股票。

All of the common stock, pre-funded warrants and accompanying common warrants are being offered by Elicio. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering..

所有的普通股、预支认股权证和附带的普通认股权证均由Elicio提供。拟议的公开募股受市场和其他条件的制约，无法保证是否或何时完成募股，也无法保证募股的实际规模或条款。。

Elicio intends to use the net proceeds from this offering together with its existing cash, cash equivalents and marketable securities, for the advancement of its development pipeline, as well as for working capital and general corporate purposes.

Elicio打算将此次发售的净收益及其现有现金、现金等价物和有价证券用于推进其发展渠道，以及用于营运资金和一般公司用途。

Jones is acting as the sole book-running manager for the offering.

琼斯是此次发售的唯一图书运营经理。

A shelf registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and became effective on June 11, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov.

与这些证券相关的货架登记声明已提交给证券交易委员会（“SEC”），并于2024年6月11日生效。与本次发行相关的初步补充招股说明书和随附招股说明书将提交给美国证券交易委员会，并可在美国证券交易委员会网站www.SEC.gov上查阅。

Electronic copies of the preliminary prospectus supplement and the accompanying prospectus related to the offering, when available, may be obtained from JonesTrading Institutional Services LLC (“Jones”), Attention: Equity Capital Markets, 325 Hudson Street, 6th Floor New York, New York 10013; email: ecm@jonestrading.com..

可从JonesTrading Institutional Services LLC（“Jones”）获得初步补充招股说明书和随附招股说明书的电子副本（如有），收件人：Equity Capital Markets，325 Hudson Street，6th Floor New York，New York 10013；电子邮件：ecm@jonestrading.com..

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售或招揽购买这些证券的要约，也不构成在根据任何州或司法管辖区的证券法律注册或资格之前，在任何州或司法管辖区出售这些证券都是非法的。。

About Elicio Therapeutics

关于Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the AMP technology, which allows for therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system’s cancer-fighting capabilities.

Elicio Therapeutics，Inc.（纳斯达克股票代码：ELTX）是一家临床阶段生物技术公司，致力于开发新型淋巴结靶向免疫疗法，用于治疗一些最具侵袭性的癌症。通过结合免疫学和免疫治疗方面的专业知识，Elicio正在利用AMP技术利用免疫系统的天然力量，该技术可以将治疗有效载荷直接传递到淋巴结，目的是增强免疫系统的抗癌能力。

By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes’ natural ability to educate, activate and amplify cancer-specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity.

通过将癌症免疫疗法靶向免疫反应的核心，AMP旨在优化淋巴结教育，激活和扩增癌症特异性T细胞的天然能力，这对于识别和消除肿瘤细胞至关重要。AMP旨在同步这些高效位点的免疫力，旨在增强免疫反应的幅度，效力，质量和持久性，从而驱动抗肿瘤活性。

Elicio’s R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations, respectively). For more information, please visit www.elicio.com.

Elicio的研发渠道包括现成的治疗性癌症疫苗ELI-002（针对mKRAS驱动的癌症）以及ELI-007和ELI-008（分别针对BRAF驱动的癌症和p53热点突变）。有关更多信息，请访问www.elicio.com。

Cautionary Note on Forward-Looking Statements

关于前瞻性陈述的警示说明

Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected.

。无法保证前瞻性陈述，实际结果可能与预测结果存在重大差异。

Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Elicio uses words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA.

Elicio没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。Elicio使用诸如“目标”、“预期”、“假设”、“相信”、“沉思”、“继续”、“可能”、“到期”、“估计”、“预期”、“目标”、“打算”、“可能”、“目标”、“计划”、“预测”、“潜在”、“定位”、“寻求”、“应该”、“目标”、“将要”、“将要”等词语，以及类似的表达方式来识别PSLRA安全港条款所涵盖的这些前瞻性陈述。

Such forward-looking statements include statements regarding, among other things, Elicio’s planned offering of its securities, statements regarding the intended use of proceeds from the offering of Elicio’s securities, and Elicio’s ability to consummate the offering of its securities. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, market risks and uncertainties and the risk that the offering of its securities will not be consummated, and the satisfaction of customary closing conditions for the offering of its securities..

此类前瞻性声明包括关于Elicio计划发行其证券的声明、关于Elicio证券发行收益的预期用途的声明以及Elicio完善其证券发行的能力。此类前瞻性声明基于我们的预期，涉及风险和不确定性；因此，由于多种因素，实际结果可能与报表中明示或暗示的结果存在重大差异，包括但不限于市场风险和不确定性，以及其证券发行无法完成的风险，以及满足其证券发行的惯例交割条件。。

New factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

新的因素不时出现，我们不可能预测所有这些因素，也不可能评估每个因素对业务的影响，或者任何因素或因素组合可能导致实际结果与任何前瞻性陈述中包含的结果存在重大差异的程度。

These risks are more fully discussed in our Annual Report on Form 10-K filed with the SEC on March 29, 2024, as amended on April 29, 2024, under the heading “Risk Factors”, and any subsequent reports and other documents filed from time to time with the SEC. Forward-looking statements included in this release are based on information available to us as of the date of this release.

。

We do not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law..

我们不承担更新此类前瞻性声明以反映本发布日期后的事件或情况的任何义务，除非法律要求。。

Investor Relations Contact

投资者关系联系人

Brian Piekos

Brian Piekos

Elicio Therapeutics

精英疗法

IR@elicio.com

IR@elicio.com

857-209-0153

857-209-0153